Month: May 2025

LONGBOAT KEY, Fla., May 28, 2025 (GLOBE NEWSWIRE) — Rumble (NASDAQ:RUM), the video-sharing platform and cloud services provider, today praised President Trump and U.S. Secretary of State Marco Rubio for their announcement that they will restrict the visas of foreign officials or nationals who engage in the censorship of Americans. As a company, Rumble has experience in this area as it is currently suing Brazilian Supreme Court Justice Alexandre de Moraes, alleging that Moraes violated the free speech protections of the First Amendment when he ordered the suspension of the U.S.-based Rumble accounts of a specific well-known, politically outspoken user. “Freedom of expression is an innate human right, so it is great to see that President Trump has the United States leading the way once again,” said Rumble CEO Chris Pavlovski. “As...

SANTA MONICA, Calif., May 28, 2025 (GLOBE NEWSWIRE) — Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in redefining how brands connect with consumers through the power of playable media, today announced that it has commenced a public offering to offer and sell securities (the “Offering”). The Company intends to use the net proceeds from this offering for general corporate and working capital needs, and the repayment of a portion of the Company’s indebtedness. The Company’s Common Stock is trading on the Nasdaq Capital Market under the symbol “SLE”. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. Aegis Capital Corp. is acting as the sole book-running manager for the offering on...

Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona. For more information, please read Neurocrine’s announcement (link). –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those...

Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — FOBI AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (“Fobi” or the “Company”) announces that it has entered into a share purchase agreement dated May 28, 2025 (the “Agreement”), with an arm’s length third party purchaser (the “Purchaser”), whereby pursuant to the Agreement, FOBI will sell to the Purchaser all of its shares in Fobi AI Germany GmbH (the “Acquired Company”, its wholly owned German subsidiary (the “Transaction”). Pursuant to the Agreement, the Purchaser will pay to FOBI an aggregate of EUR 1,540,000.00 consisting of a cash purchase price in the amount of EUR 1,400,000.00 (the “Purchase Price”) and an additional purchase price in the amount of EUR 140,000.00, which will be paid by the Purchaser to the Acquired Company on behalf of FOBI after assumption by the Purchaser of FOBI’s obligations...

LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) — Jena Acquisition Corporation II (“Jena II” or the “Company”) announced today that it priced its initial public offering of 20,000,000 units at $10.00 per unit. The units will be listed on the New York Stock Exchange (“NYSE”) and trade under the ticker symbol “JENA.U” beginning May 29, 2025. Each unit consists of one Class A ordinary share and one right entitling the holder thereof to receive one-twentieth of one Class A ordinary share upon the consummation of an initial business combination. The Class A ordinary shares and rights comprising the units are expected to begin separate trading no later than the 52nd day following this date. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the NYSE under the...

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig”) and Streamex Exchange Corporation (“Streamex”), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies’ leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment:Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of experience in capital markets, having held senior executive roles at OppenheimerFunds, and Wafra Inc. At Wafra Inc.,...

Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced that clinical and preclinical data from the Company’s off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European Congress of Rheumatology (EULAR 2025), being held in Barcelona, Spain on June 11-14, 2025. The Company has been selected to provide an oral presentation featuring clinical data from...